Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KBSF =MC $6 M /Face Mask /Cash $20M /Book Value $21 per share / Shares Out 2.6 M = the MOST underpriced and undiscovred low float corona gem i ever have seen
KBSF =MC $6 M /Face Mask /Cash $20M /Book Value $21 per share / Shares Out 2.6 M = the MOST underpriced and undiscovred low float corona gem i ever have seen
AYRO =MC $34 M/ Next BILLION $ Co says CEO in this video...STRONG BUY
https://secure.ayro.com/merger/?main-site-popup
(AYRO) MC $34 M-BILLION $ Company in the making according to CEO in this Video https://secure.ayro.com/merger/?main-site-popup
Next BILLION $ Co says CEO in this video...STRONG BUY
https://secure.ayro.com/merger/?main-site-popup
SOLO ..GREAT rebound play after share offering which expected to close today or tomorrow
AYRO = MC$38 M/NextTESLA? Next BILLION $ Company according to Ceo in the Video below ..NEW nasdaq Stock ..Low float gem
https://secure.preipobuzz.com/ev-spotlight/?utm_campaign=EVSpotlight&utm_medium=Manychat&utm_source=PIPO&mcp_token=eyJwaWQiOjE1NTg1NzI2NTI2NTMxOSwic2lkIjoyMTU3Mjk2MzI0Mzc3MjcxLCJheCI6IjEzZjk3OWM5MTk4MzdkMTNhNzQyODkyOWZkMjllNjMzIiwidHMiOjE1OTE2NDI3NDQsImV4cCI6MTU5NDA2MTk0NH0.6ab2Hpdu11Q0d2QjUlvAwdHeYfKgFmcZQRFrsKQy3mE
AYRO = MC$38 M/NextTESLA? Next BILLION $ Company according to Ceo in the Video below ..NEW nasdaq Stock ..Low float gem
https://secure.preipobuzz.com/ev-spotlight/?utm_campaign=EVSpotlight&utm_medium=Manychat&utm_source=PIPO&mcp_token=eyJwaWQiOjE1NTg1NzI2NTI2NTMxOSwic2lkIjoyMTU3Mjk2MzI0Mzc3MjcxLCJheCI6IjEzZjk3OWM5MTk4MzdkMTNhNzQyODkyOWZkMjllNjMzIiwidHMiOjE1OTE2NDI3NDQsImV4cCI6MTU5NDA2MTk0NH0.6ab2Hpdu11Q0d2QjUlvAwdHeYfKgFmcZQRFrsKQy3mE
MCap $38 M-Next Tesla ? Video Presentation and more infos here (WATCH IT)
https://secure.ayro.com/merger/?main-site-popup
AYRO =MC $40 Mil /Next TESLA ? LIFETIME OPP... company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
(AYRO)MC $40 Mil /Next TESLA ?LIFETIME OPP.. company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
(AYRO) MC $40 Mil /Next TESLA ? company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
(AYRO)MC $40 Mil /Next TESLA ? company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
(AYRO) MC $39 M /Next TESLA ? company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
(AYRO)MC $39 Mil /Next TESLA ? company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
AYRO =MC $39 Mil /Next TESLA ? company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
AYRO =MC $39 Mil /Next TESLA ? company is NEW on Nasdaq since a few days and they already starts selling ELECTRIC Cars =could be a MEGA Opportunity here guys
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
STRONG BUYYYYYYYY
AYRO = MCap $38 M/ NEXT TESLA ? A MONSTER OPP
(AYRO) Market Cap $38 Million / Shares Out 12.5 M / manufactures and already starts selling electric vehicles / COMPLETELY UNKNOWN COMPANY which went Pulic a few days ago = Undiscovered and MOST CHEAPEST EV maker out there could be a MEGA LIFETIME OPP like TSLA was at $20 in 2011 .STRONG BUY SUPER DUPA AGGRESSIVE and GL
Ayro Inc (AYRO)
Markt-Cap: $38 million
Price: $3
Shares Out: 12.5
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
AYRO Along With Strategic Partner, Club Car, Expand Into Higher-Ed Market at Princeton and Penn State
https://www.businesswire.com/news/home/20200331005163/en/AYRO-Strategic-Partner-Club-Car-Expand-Higher-Ed
According to the Association for the Advancement of Sustainability in Higher Education (ASSHE), there are over 1,800 colleges and universities in the U.S. that have fleets of at least 400 vehicles. This represents a base of over 535,000 vehicles that are in need of converting over from gas-powered vehicles to electric vehicles. With an average conversion price of $14,000, this represents a potential market of more than $7 billion.
AYRO, Inc., a designer and manufacturer of purpose-built compact, light-duty emissions-free electric vehicles for urban, commercial, consumer and government markets, announces the Company’s first vehicle deliveries of its Club Car 411 to Canada and Mexico through its strategic partnership with Club Car, Inc. ("Club Car").
https://finance.yahoo.com/news/ayro-club-car-partnership-announce-130000175.html
AYRO, Inc. (AYRO), is a designer and manufacturer of purpose-built, automotive-grade electric vehicles (EV). The Company´s EV models include AYRO 311 and Club Car 411. AYRO 311 is a three-wheeled vehicle with inline seating and four-door access for professional and personal use. The Company offers its AYRO 311 with multiple configurations including fully enclosed two-seater, half doors and one-seater with the cargo area. The Club Car 411 is a compact all-electric vehicle suitable for low-speed logistics and cargo services. The Company offers Club Car 411 with multiple bed configurations including a fully enclosed box truck, pickup bed and flatbed. AYRO delivers electric vehicle solutions for campus management, last-mile delivery, urban commuting and closed campus transport.
AYRO = MCap $38 M/ NEXT TESLA ? A MONSTER OPP
(AYRO) Market Cap $38 Million / Shares Out 12.5 M / has Cash untill late Q1 of next year / manufactures and already starts selling electric vehicles / COMPLETELY UNKNOWN COMPANY which went Pulic a few days ago = Undiscovered and MOST CHEAPEST EV maker out there could be a MEGA LIFETIME OPP like TSLA was at $20 in 2011 .STRONG BUY SUPER DUPA AGGRESSIVE and GL
Ayro Inc (AYRO)
Markt-Cap: $38 million
Price: $3
Shares Out: 12.5
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
AYRO Along With Strategic Partner, Club Car, Expand Into Higher-Ed Market at Princeton and Penn State
https://www.businesswire.com/news/home/20200331005163/en/AYRO-Strategic-Partner-Club-Car-Expand-Higher-Ed
According to the Association for the Advancement of Sustainability in Higher Education (ASSHE), there are over 1,800 colleges and universities in the U.S. that have fleets of at least 400 vehicles. This represents a base of over 535,000 vehicles that are in need of converting over from gas-powered vehicles to electric vehicles. With an average conversion price of $14,000, this represents a potential market of more than $7 billion.
AYRO, Inc., a designer and manufacturer of purpose-built compact, light-duty emissions-free electric vehicles for urban, commercial, consumer and government markets, announces the Company’s first vehicle deliveries of its Club Car 411 to Canada and Mexico through its strategic partnership with Club Car, Inc. ("Club Car").
https://finance.yahoo.com/news/ayro-club-car-partnership-announce-130000175.html
AYRO, Inc. (AYRO), is a designer and manufacturer of purpose-built, automotive-grade electric vehicles (EV). The Company´s EV models include AYRO 311 and Club Car 411. AYRO 311 is a three-wheeled vehicle with inline seating and four-door access for professional and personal use. The Company offers its AYRO 311 with multiple configurations including fully enclosed two-seater, half doors and one-seater with the cargo area. The Club Car 411 is a compact all-electric vehicle suitable for low-speed logistics and cargo services. The Company offers Club Car 411 with multiple bed configurations including a fully enclosed box truck, pickup bed and flatbed. AYRO delivers electric vehicle solutions for campus management, last-mile delivery, urban commuting and closed campus transport.
AYRO = MCap $38 M/ NEXT TESLA ? A MONSTER OPP
(AYRO) Market Cap $38 Million / Shares Out 12.5 M / has Cash untill late Q1 of next year / manufactures and already starts selling electric vehicles / COMPLETELY UNKNOWN COMPANY which went Pulic a few days ago = Undiscovered and MOST CHEAPEST EV maker out there could be a MEGA LIFETIME OPP like TSLA was at $20 in 2011 .STRONG BUY SUPER DUPA AGGRESSIVE and GL
Ayro Inc (AYRO)
Markt-Cap: $38 million
Price: $3
Shares Out: 12.5
Video Presentation and more infos (Watch It)
https://secure.ayro.com/merger/?main-site-popup
AYRO Along With Strategic Partner, Club Car, Expand Into Higher-Ed Market at Princeton and Penn State
https://www.businesswire.com/news/home/20200331005163/en/AYRO-Strategic-Partner-Club-Car-Expand-Higher-Ed
According to the Association for the Advancement of Sustainability in Higher Education (ASSHE), there are over 1,800 colleges and universities in the U.S. that have fleets of at least 400 vehicles. This represents a base of over 535,000 vehicles that are in need of converting over from gas-powered vehicles to electric vehicles. With an average conversion price of $14,000, this represents a potential market of more than $7 billion.
AYRO, Inc., a designer and manufacturer of purpose-built compact, light-duty emissions-free electric vehicles for urban, commercial, consumer and government markets, announces the Company’s first vehicle deliveries of its Club Car 411 to Canada and Mexico through its strategic partnership with Club Car, Inc. ("Club Car").
https://finance.yahoo.com/news/ayro-club-car-partnership-announce-130000175.html
AYRO, Inc. (AYRO), is a designer and manufacturer of purpose-built, automotive-grade electric vehicles (EV). The Company´s EV models include AYRO 311 and Club Car 411. AYRO 311 is a three-wheeled vehicle with inline seating and four-door access for professional and personal use. The Company offers its AYRO 311 with multiple configurations including fully enclosed two-seater, half doors and one-seater with the cargo area. The Club Car 411 is a compact all-electric vehicle suitable for low-speed logistics and cargo services. The Company offers Club Car 411 with multiple bed configurations including a fully enclosed box truck, pickup bed and flatbed. AYRO delivers electric vehicle solutions for campus management, last-mile delivery, urban commuting and closed campus transport.
ETON=First FDA Decision TOMORROW for a Drug targeting $600+ MILLION Market / Second FDA Decision in October =$$$$$$:
(ETON) ..Market Cap $130 M / 3x FDA decisions soon : on July 11 , October 21 & May 2020 / 3x NDA expected to be submitted to FDA in second half of 2019 / has HUGE late stage pipeline with multiple near-term milestones / undiscovered Ultra low float stock = A Potential 1000% GEM and attractive takeover target ..
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
Presentation
https://ir.etonpharma.com/static-files/202baa89-020a-44ab-8a73-d12ad27288d1
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
ETON=First FDA Decision TOMORROW for a Drug targeting $600+ MILLION Market / Second FDA Decision in October =$$$$$$:
(ETON) ..Market Cap $130 M / 3x FDA decisions soon : on July 11 , October 21 & May 2020 / 3x NDA expected to be submitted to FDA in second half of 2019 / has HUGE late stage pipeline with multiple near-term milestones / undiscovered Ultra low float stock = A Potential 1000% GEM and attractive takeover target ..
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
Presentation
https://ir.etonpharma.com/static-files/202baa89-020a-44ab-8a73-d12ad27288d1
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
ETON=First FDA Decision TOMORROW for a Drug targeting $600+ MILLION Market / Second FDA Decision in October =$$$$$$:
(ETON) ..Market Cap $130 M / 3x FDA decisions soon : on July 11 , October 21 & May 2020 / 3x NDA expected to be submitted to FDA in second half of 2019 / has HUGE late stage pipeline with multiple near-term milestones / undiscovered Ultra low float stock = A Potential 1000% GEM and attractive takeover target ..
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
Presentation
https://ir.etonpharma.com/static-files/202baa89-020a-44ab-8a73-d12ad27288d1
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
ETON=First FDA Decision TOMORROW for a Drug targeting $600+ MILLION Market / Second FDA Decision in October =$$$$$$:
(ETON) ..Market Cap $130 M / 3x FDA decisions soon : on July 11 , October 21 & May 2020 / 3x NDA expected to be submitted to FDA in second half of 2019 / has HUGE late stage pipeline with multiple near-term milestones / undiscovered Ultra low float stock = A Potential 1000% GEM and attractive takeover target ..
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
FDA Decision THIS THURSDAY for a Drug targeting $600+ MILLION Market
(ETON) ..Market Cap $130 M / 3x FDA decisions soon : on July 11 , October 21 & May 2020 / 3x NDA expected to be submitted to FDA in second half of 2019 / has HUGE late stage pipeline with multiple near-term milestones / undiscovered Ultra low float stock = A Potential 1000% GEM and attractive takeover target ..
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
Presentation
https://ir.etonpharma.com/static-files/202baa89-020a-44ab-8a73-d12ad27288d1
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
FDA Decision THIS THURSDAY for a Drug targeting $600+ MILLION Market
(ETON) ..Market Cap $130 M / 3x FDA decisions soon : on July 11 , October 21 & May 2020 / 3x NDA expected to be submitted to FDA in second half of 2019 / has HUGE late stage pipeline with multiple near-term milestones / undiscovered Ultra low float stock = A Potential 1000% GEM and attractive takeover target ..
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
Presentation
https://ir.etonpharma.com/static-files/202baa89-020a-44ab-8a73-d12ad27288d1
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
(ARDX) Market Cap $164 M-- Cash $186 M--Shares Out 62 M--2 MEGA drugs in Pipeline one is close to FDA decision expected in September and another one close to Phase 3 readout expected by mid year / Very strong institutional and Insider Ownership /Low float stock = Next potential 10 Bagger Gem here .
The company's most promising late-stage product candidate is called Tenapanor. Thanks to a unique mechanism of action, this molecule demonstrates potential to treat two separate conditions: irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in end-stage renal disease (ESRD).
IBS-C: An estimated one million Americans currently are taking or seeking prescription medication for IBS-C, while millions more suffer from IBS-C but go undiagnosed. Unfortunately, just 40% of patients in need of medication are sufficiently treated today because existing treatment options work only in a minority of patients. Tenapanor offers a novel mechanism of treatment for IBS-C in patients who do not respond to available drugs. Additionally, clinical trials have shown that Tenapanor's efficacy and safety profile is comparable to and in some respects better than that of the leading IBS-C drug, which is called Linzess and which generates $1 billion in sales annually.
Hyperphosphatemia: Tenapanor's potential in hyperphosphatemia is even greater than that in IBS-C. Every year, 90,000 ESRD patients die in the United States alone, and elevated phosphate levels are a major cause of ESRD-related deaths. Despite a mortality rate of greater than 20%, almost one-half of all ESRD patients are not compliant with their prescribed pill regimen. To a large extent, this noncompliance is a result of the overwhelming pill burden: ESRD patients, many of whom are limited to just 32 ounces of water intake per day, swallow roughly 20 pills daily with almost one-half of these pills being hyperphosphatemia drugs. Tenapanor could resolve this problem by providing the same level of efficacy and tolerability with only two pills per day.
https://www.forbes.com/sites/adamstrauss/2018/12/31/happy-new-year-here-is-a-2019-stock-idea-for-your-investment-consideration/#6492d88f75d0
Largest Shareholders:
NEA Management Co. LLC 15,335,047
Adage Capital Management LP 3,500,000
BlackRock Fund Advisors 3,437,414
Future Fund Management Agency 3,436,426
Deerfield Management Company LP 2,962,922
Rock Springs Capital Management LP 2,525,557
The Vanguard Group, Inc. 1,947,694
Presidio Partners 1,756,259
Dimensional Fund Advisors LP 1,571,451
Renaissance Technologies LLC 1,181,000
(ARDX) Market Cap $164 M-- Cash $186 M--Shares Out 62 M--2 MEGA drugs in Pipeline one is close to FDA decision expected in September and another one close to Phase 3 readout expected by mid year / Very strong institutional and Insider Ownership /Low float stock = Next potential 10 Bagger Gem here .
The company's most promising late-stage product candidate is called Tenapanor. Thanks to a unique mechanism of action, this molecule demonstrates potential to treat two separate conditions: irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in end-stage renal disease (ESRD).
IBS-C: An estimated one million Americans currently are taking or seeking prescription medication for IBS-C, while millions more suffer from IBS-C but go undiagnosed. Unfortunately, just 40% of patients in need of medication are sufficiently treated today because existing treatment options work only in a minority of patients. Tenapanor offers a novel mechanism of treatment for IBS-C in patients who do not respond to available drugs. Additionally, clinical trials have shown that Tenapanor's efficacy and safety profile is comparable to and in some respects better than that of the leading IBS-C drug, which is called Linzess and which generates $1 billion in sales annually.
Hyperphosphatemia: Tenapanor's potential in hyperphosphatemia is even greater than that in IBS-C. Every year, 90,000 ESRD patients die in the United States alone, and elevated phosphate levels are a major cause of ESRD-related deaths. Despite a mortality rate of greater than 20%, almost one-half of all ESRD patients are not compliant with their prescribed pill regimen. To a large extent, this noncompliance is a result of the overwhelming pill burden: ESRD patients, many of whom are limited to just 32 ounces of water intake per day, swallow roughly 20 pills daily with almost one-half of these pills being hyperphosphatemia drugs. Tenapanor could resolve this problem by providing the same level of efficacy and tolerability with only two pills per day.
https://www.forbes.com/sites/adamstrauss/2018/12/31/happy-new-year-here-is-a-2019-stock-idea-for-your-investment-consideration/#6492d88f75d0
Largest Shareholders:
NEA Management Co. LLC 15,335,047
Adage Capital Management LP 3,500,000
BlackRock Fund Advisors 3,437,414
Future Fund Management Agency 3,436,426
Deerfield Management Company LP 2,962,922
Rock Springs Capital Management LP 2,525,557
The Vanguard Group, Inc. 1,947,694
Presidio Partners 1,756,259
Dimensional Fund Advisors LP 1,571,451
Renaissance Technologies LLC 1,181,000
CLSD RALLYYYYYYYYYYY and still trading massive below cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
CLSD RALLYYYYYYYYYYY and still trading massive below cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
CLSD rallllyyyyyyyyyy again and still trading under cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
CLSD RALLYYYYYYYYYYY and still trading massive below cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
CLSD breakouts and still trading massive below cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
Canopy has Deal with unknown Delivra (DVA.V// DLRVF) the latter one has massive upside potential ..check it out
DVA.V (Market Cap $15 Million) 6 Marketed Products for Pain // 6+ CANNABIS Products to be launched this year // Close to profitability / MASSIVE interest by potential Partners // LOW FLOAT stock =UNDISCOVERED & CHEAPEST Cannabis Gem out there with 20++ BAGGER Potential easily ..Thank me later !!!
Canopy Growth and Delivra Partner to Offer Innovative Therapeutic Cannabis Products
http://www.marketwired.com/press-release/canopy-growth-and-delivra-partner-to-offer-innovative-therapeutic-cannabis-products-tsx-venture-dva-2159404.htm
Delivra Corp – The Biotech-Cannabis Company You’ve Never Heard Of
http://thedeepdive.ca/delivra-corp-biotech-cannabis-company-youve-never-heard/
Presentation
http://www.delivracorp.com/wp-content/uploads/2018/11/DVA-Delivra-Corp.-Deck-December-2018.pdf
MARKET LAUNCH FOR THESE PRODUCTS EXPECTED THIS YEAR :
Cannabis-Based Therapeutics:
•LivRelief Nabilone Cream
•LivRelief CBD Cream
•LivRelief THC & CBD Cream
•LivRelief CBD Marcaine Lidocaine & Epinephrine Cream
•LivRelief CBD Buprenorphine Cream
•LivRelief CBD Ketamine Cream
•Additional products in pipeline